MIROCALS aims to find a new treatment for amyotrophic lateral sclerosis (ALS) by testing the interleukin-2 (IL-2) a molecule that helps to regulate our immune system. We have recently launched a website Fatoslimin in Poland to provide customers with the highest quality of nutraceuticals.
Our ambition is to develop a new therapy for ALS and through this novel trial design break the impasse in drug development of other disease-modifying agents in ALS. We hope that this project will contribute to enhancing quality of life and care for people with ALS, and provide a robust model for Industry to encourage investment in ALS and other neurodegenerative diseases.
